Multifunctional magnetic Fe$_3$O$_4$ nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance

Yanyan Ren 1,2, *
Haijun Zhang 1,2, *
Baoan Chen 1
Jian Cheng 1
Xiaohui Cai 1
Ran Liu 1
Guohua Xia 1
Weiwei Wu 1
Shuai Wang 1
Jiahua Ding 1
Chong Gao 1
Jun Wang 1
Wen Bao 1
Lei Wang 1
Liang Tian 1
Huihui Song 1
Xuemei Wang 1,2

1 Department of Hematology and Oncology, Key Medical Discipline, Jiangsu Province, Zhongda Hospital, and Faculty of Oncology, Medical School, Nanjing, 2 State Key Laboratory of Bioelectronics, Southeast University, Nanjing, People’s Republic of China

* These authors contributed equally to this work

Background: Multidrug resistance in cancer is a major obstacle for clinical therapeutics, and is the reason for 90% of treatment failures. This study investigated the efficiency of novel multifunctional Fe$_3$O$_4$ magnetic nanoparticles (Fe$_3$O$_4$-MNP) combined with chemotherapy and hyperthermia for overcoming multidrug resistance in an in vivo model of leukemia.

Methods: Nude mice with tumor xenografts were randomly divided into a control group, and the treatment groups were allocated to receive daunorubicin, 5-bromotetrandrine (5-BrTet) and daunorubicin, Fe$_3$O$_4$-MNP, and Fe$_3$O$_4$-MNP coloaded with daunorubicin and 5-bromotetrandrine (Fe$_3$O$_4$-MNP-DNR-5-BrTet), with hyperthermia in an alternating magnetic field. We investigated tumor volume and pathology, as well as P-glycoprotein, Bcl-2, Bax, and caspase-3 protein expression to elucidate the effect of multimodal treatment on overcoming multidrug resistance.

Results: Fe$_3$O$_4$-MNP played a role in increasing tumor temperature during hyperthermia. Tumors became significantly smaller, and apoptosis of cells was observed in both the Fe$_3$O$_4$-MNP and Fe$_3$O$_4$-MNP-DNR-5-BrTet groups, especially in the Fe$_3$O$_4$-MNP-DNR-5-BrTet group, while tumor volumes in the other groups had increased after treatment for 12 days. Furthermore, Fe$_3$O$_4$-MNP-DNR-5-BrTet with hyperthermia noticeably decreased P-glycoprotein and Bcl-2 expression, and markedly increased Bax and caspase-3 expression.

Conclusion: Fe$_3$O$_4$-MNP-DNR-5-BrTet with hyperthermia may be a potential approach for reversal of multidrug resistance in the treatment of leukemia.

Keywords: magnetic nanoparticles, daunorubicin, 5-bromotetrandrine, multidrug resistance, hyperthermia

Introduction

Multidrug resistance is the phenomenon of cross-resistance of mammalian cells to a number of anticancer agents following exposure to one type of drug, and is a major obstacle in cancer chemotherapy, especially in the treatment of leukemia. Although the mechanism of multidrug resistance is complex, it is mainly due to the activation of a family of energy-dependent drug efflux pumps, such as P-glycoprotein, which can transport drugs out of the cell. On the other hand, alternating expression of apoptosis-related proteins, such as Bcl-2, caspase-3, and Bax, in multidrug-resistant cancer cells causes a lack of response to many front-line chemotherapeutic agents. Therefore, regulation of P-glycoprotein and apoptosis-related protein has attracted research interest in an effort to overcome multidrug resistance in the treatment of cancer.

In recent years, the need to overcome multidrug resistance using a rational approach has been emphasized. Chinese herbal medicine, nanoparticles, and hyperthermia have contributed a lot to this line of research. It is well known that hyperthermia adjuvant
to multidrug-resistant tumors in vivo, but temperature has been difficult to control. Fortunately, recent evidence in the literature suggests that magnetic nanoparticles can be used to improve the efficiency of hyperthermia and to regulate temperature at a stable level. The magnetic nanoparticles used for hyperthermia have a maximum temperature known as the Curie temperature, which is related to both magnetism and composition of the nanoparticles, but is not related to their concentration. Furthermore, the nanoparticles can be used to deliver anticancer drugs and reversal agents to improve the efficiency of treatment as well as to overcome drug resistance.11,12

Nowadays, some Chinese herbal medicines are considered to be able to reverse multidrug resistance in the treatment of cancer. Previous research has demonstrated that 5-bromotetrandrine (5-BrTet) can partly inhibit the function of P-glycoprotein, suppress antiapoptosis, and accumulate anticancer drugs in vivo and in vitro. Our own research has also demonstrated that Fe3O4 magnetic nanoparticles (MNP) enhance the efficiency of 5-BrTet and daunorubicin (DNR) in overcoming multidrug resistance in vivo and in vitro models of cancer. Thus, we suspected that Fe3O4-MNP-DNR-5-BrTet with hyperthermia in an alternating magnetic field, as a multifunctional strategy, may have improved therapeutic efficiency. In the present study, we investigated tumor volume, pathology, and expression of P-glycoprotein, Bcl-2, Bax, and caspase-3 proteins to elucidate the effect of multimodal treatment in overcoming multidrug resistance after nude mice with tumor xenografts were treated with Fe3O4-MNP-DNR-5-BrTet and hyperthermia.

Materials and methods

Main agents
Adriamycin was purchased from Hisun Pharmaceutical Co, Ltd (Zhejiang, China); DNR from Main Luck Pharmaceuticals Inc (Shenzhen, China); 5-bromotetrandrin from Kang Hong Pharmaceuticals Inc (Chengdu, China); RPMI-1640 from Gibco Chemical Co (Carlsbad, CA); trichloride ferric, ferrous sulfate, oleic acid, and ammonium hydroxide from Shanghai Hanguang Chemical Reagent Co, Ltd (Shanghai, China); Pluronic F-127 from Sigma-Aldrich (St Louis, MO); hematoxylin-eosin staining kit from Beyotime Institute of Biotechnology (Shanghai, China); fetal bovine serum from Hangzhou Sijiqing Biological Engineering Materials Co, Ltd (Hangzhou, China); and monoclonal antibodies to Bax, Bcl-2, caspase-3, and P-glycoprotein from Santa Cruz Biotechnology Inc (Santa Cruz, CA).

Cell line and cell culture
A resistant human chronic myeloid leukemia cell line, K562/A02, was received as a gift from the Institute of Hematology, Chinese Academy of Medical Sciences. It was established by stepwise selection with an increasing concentration of adriamycin. The cells were maintained in RPMI-1640 medium with 10% fetal bovine serum, 100 µg/mL penicillin, and 100 µg/mL streptomycin at 37°C in a humidified 5% CO2 atmosphere. To maintain a multidrug-resistant phenotype, the cell line was cultured in a medium containing 1 g/mL adriamycin for at least 1 week before use.

Experimental animals
Athymic nude BALB/c mice (4 weeks of age, 16–20 g in weight) were purchased from the Shanghai National Center for Laboratory Animals. They were maintained in a specific pathogen-free facility on a 12-hour light/dark cycle and fed with sterile food. The indoor temperature was maintained at 22°C and humidity ranged from 40% to 50%. All animal experiments were performed in adherence with the Guidelines for the Care and Use of Laboratory Animals of the National Institutes of Health.

Preparation of Fe3O4-MNP and Fe3O4-MNP-DNR-5-BrTet
As described earlier, 26 g of ferric chloride hexahydrate, 18 g of ferrous sulfate heptahydrate, 5 g of oleic acid, and 50 mL of ammonium hydroxide (25%) were prepared for chemical reaction in nitrogen. The iron oxide nanoparticles were then prepared by coprecipitation of Fe3+ and Fe2+ with ammonium hydroxide. The prepared oleic acid-coated iron oxide nanoparticles were maintained at a high temperature and further modified with Pluronic F-127. Finally, the solution was gradually cooled to room temperature and extracted using a magnet, as previously described.

After the aqueous dispersion of oleic acid-coated and Pluronic-modified iron oxide nanoparticles were synthesized, the already prepared hydrophobic DNR and 5-Br-Tet were added dropwise into the aqueous dispersion by vigorous magnetic force and stirring overnight to force the DNR and 5-Br-Tet to enter in the oleic acid layer. The effective drug-loading rate of DNR and 5-Br-Tet was approximately 8.25% (DNR:5-Br-Tet = 1:1 [w/w]), determined by high-performance liquid chromatography with a fluorescence detector.
**Multidrug-resistant leukemia xenograft model in nude mice**

The nude mice were maintained in a specific pathogen-free facility for 7 days, and then injected with K562/A02 cells to establish a human multidrug-resistant leukemia xenograft model. Briefly, $1 \times 10^7$ K562/A02 cells suspended in 0.2 mL of RPMI-1640 medium were injected subcutaneously into the left posterior axilla of the nude mice. After the nude mice were injected with K562/A02 cells for about a week, a lump with skin-colored peplos was observed in the left posterior axilla of each mouse, which continued to grow larger until intervention, indicating that this lump was the multidrug-resistant leukemia xenograft.

**Treatment protocol**

When the tumor size was $950 \pm 150 \text{ mm}^3$, 24 tumor-bearing nude mice were randomly divided into five groups. The treatment protocol included Group A, a negative control group in which each mouse was treated with 0.9% normal saline 0.2 mL; Group B, treated with DNR 1 mg/kg; Group C, treated with 5-BrTet 1 mg/kg and DNR 1 mg/kg; Group D, treated with Fe$_3$O$_4$-MNP 22 mg/kg; and Group E, treated with Fe$_3$O$_4$-MNP-DNR-5-BrTet 24 mg/kg, in which DNR was 1 mg/kg and 5-BrTet was 1 mg/kg. After administration of the study treatment, all mice were kept in an alternating magnetic field at a frequency of 219 kHz and a variable field strength of 10.5–310.1 kA/m for 40 minutes. Thereafter, the tumor inhibition rate in the mice was calculated and tumor volume growth characteristics were recorded for 12 days before sacrifice. The xenograft tumor was then harvested and processed for histopathologic analysis and determination of protein expression.

**Tumor volume and inhibition rate**

To evaluate the effect of the study treatment, two diameters of tumor were measured with digital calipers, and then tumor size was calculated using the following formulae:

$$V = \frac{1}{2} \times a \times b^2$$

where $V$ is tumor volume, $a$ is the longest diameter, and $b$ is the shortest diameter.

$$\text{RTV} = \frac{V_t}{V_0}$$

where RTV is relative tumor volume, $V_0$ represents the first day before treatment, and $V_t$ represents the $x$ day after treatment.

**Histopathologic examination of tumors**

After the xenograft tumor was harvested, it was immediately fixed in 4% paraformaldehyde, dehydrated in a graded series of alcohol, and then embedded in paraffin. Slices 0.5 mm thick were cut and stained with hematoxylin and eosin for microscopic examination. All sections were observed in a blinded manner, and photographed using a 400× light microscope.

**Western blot assays**

Samples of tumor tissue weighing 0.1 g was collected from each mouse and homogenized for detection of P-glycoprotein, Bcl-2, Bax, and caspase-3. Briefly, the tissues were extracted with Triton X-100, and the proteins were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then electroblotted onto a polyvinylidene difluoride membrane (BioRad Laboratories, Hercules, CA). The membrane was blocked with buffer containing 10% fat-free dry milk. Thereafter, mouse anti-Bcl-2 antibody (1:400), mouse anti-Bax antibody (1:400), mouse anti-caspase-3 antibody (1:400), mouse anti-P-glycoprotein antibody (1:200), and anti-β-actin (1:400) were used as the primary antibody overnight, and then subsequently incubated with a secondary horseradish peroxidase-conjugated antirabbit antibody (1:1000) for 1 hour at room temperature. The band was detected using an enhanced chemiluminescence system.

**Statistical analysis**

All experimental data were expressed as the mean ± standard deviation and analyzed using SPSS software (version 13.0; SPSS Inc, Chicago, IL). A $P$ value of $<0.05$ was considered to be statistically significant.

**Results**

**Characteristics of Fe$_3$O$_4$-MNP**

An image of the oleic acid-Pluronic-modified Fe$_3$O$_4$-MNP is shown in Figure 1A. As observed by transmission electronic microscopy, the nanoparticles had a spherical shape and were dispersed uniformly. The size of the Fe$_3$O$_4$-MNP ranged from 13.5 to 23.5 nm, and the mean size was 18.44 ± 1.84 nm (Figure 1B).
Influence of extreme and moderate heat on tumors

After treatment with hyperthermia for different periods of time, the temperature change at the tumor site was determined and is shown in Table 1. It can be seen that the tumor temperature in the mice treated with Fe₃O₄-MNP increased to 41.71°C ± 1.52°C and in those treated with Fe₃O₄-MNP-DNR-5-BrTet the temperature increased to 41.56°C ± 1.8°C after 20 minutes of hyperthermia. The tumor temperature was higher in these two groups than in the other groups, but there were no significant difference between them. Furthermore, no obvious change in temperature was observed in the mice not treated with Fe₃O₄-MNP throughout the study. Interestingly, except for the increased temperature at the tumor site, the mice treated with Fe₃O₄-MNP or Fe₃O₄-MNP-DNR-5-BrTet did not show any increase in temperature elsewhere. These results show that Fe₃O₄-MNP played an important role in the temperature changes at the tumor site in response to both extreme and moderate hyperthermia.

Volume and inhibitory rate in tumor tissue

All the mice were alive and no adverse reactions were observed during the 12 days of treatment. The tumor volume was smaller and smaller in a time-dependent manner in both the Fe₃O₄-MNP and Fe₃O₄-MNP-DNR-5-BrTet groups, especially in the Fe₃O₄-MNP-DNR-5-BrTet group. In contrast, the tumor volume in the other groups became increasingly large, and was markedly larger in the DNR and control groups than in the DNR and 5Br-Tet groups (Figure 2). Further, the RTV in the Fe₃O₄-MNP and Fe₃O₄-MNP-DNR-5-BrTet groups was much lower than in other groups (P < 0.05) at day 12 after treatment, as shown in Figure 3. Interestingly, from day 4 onwards, the RTV decreased markedly more rapidly in the Fe₃O₄-MNP-DNR-5-BrTet group than in the Fe₃O₄-MNP group (P < 0.05, Figure 3).

The tumor inhibition rate was higher in both the Fe₃O₄-MNP and Fe₃O₄-MNP-DNR-5-BrTet groups than in the DNR group or in the group treated with DNR combined with 5-BrTet (P < 0.05), and the change was particularly marked in the Fe₃O₄-MNP-DNR-5-BrTet group (Figure 5). The inhibition rate was 75.92% ± 5.77% in the Fe₃O₄-MNP-DNR-5-BrTet group and 65.31% ± 5.66% in the Fe₃O₄-MNP group, and higher than in the DNR (10.73% ± 4.58%) and DNR and 5-BrTet groups (31.04% ± 8.22%; P < 0.05), suggesting that Fe₃O₄-MNP-DNR-5-BrTet with hyperthermia had the strongest effect on tumor inhibition rate in a multidrug-resistant leukemia tumor model.

Table 1 Temperature change of tumor site after treatment for different times (mean ± SD)

<table>
<thead>
<tr>
<th>Group</th>
<th>Temperature (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 minutes</td>
</tr>
<tr>
<td>A</td>
<td>30.85 ± 1.49</td>
</tr>
<tr>
<td>B</td>
<td>31.05 ± 1.96</td>
</tr>
<tr>
<td>C</td>
<td>31.02 ± 1.88</td>
</tr>
<tr>
<td>D</td>
<td>30.86 ± 1.96</td>
</tr>
<tr>
<td>E</td>
<td>30.88 ± 1.79</td>
</tr>
</tbody>
</table>

Notes: Group A, control; Group B, DNR; Group C, DNR and 5-BrTet; Group D, Fe₃O₄-MNP; Group E, Fe₃O₄-MNP-DNR-5-BrTet.

Abbreviations: DNR, daunorubicin; 5-BrTet, 5-bromotetrandrine; Fe₃O₄-MNP, magnetic nanoparticles of Fe₃O₄.
Histopathologic examination of tumor tissue

Representative histopathological images showed the neoplastic cells to have spherical heterogeneity with karyomegaly and dark blue nuclei, indicating more clear-edged mitotic figures (indicated by red arrows in Figure 5A and B). Few apoptotic cells were observed in the DNR-5-BrTet group, indicated by black arrows (Figure 5C). Notably, a reasonable quantity of apoptotic cells and an obvious apoptosis phenomenon were observed in the Fe3O4-MNP-DNR-5-BrTet and Fe3O4-MNP groups; karyopyknosis and karyorrhexis could be observed in the apoptotic cells, especially in the Fe3O4-MNP-DNR-5-BrTet group. Moreover, some brown punctiforms in localized areas could be seen in the Fe3O4-MNP and Fe3O4-MNP-DNR-5-BrTet groups, suggesting that Fe3O4-MNP can be targeted successfully to tumor tissue using additional hyperthermia.

P-glycoprotein, Bcl-2, Bax, and caspase-3 protein expression

P-glycoprotein, Bcl-2, Bax and caspase-3 protein expression levels were detected by Western blotting, and are shown in Figure 6. There was no significant difference in relative intensity between any of these proteins in the control and DNR groups. However, compared with the other groups, Bcl-2 protein expression was markedly decreased and that of Bax and caspase-3 proteins was markedly increased in the Fe3O4-MNP and Fe3O4-MNP-DNR-5-BrTet groups (P < 0.05). Also, the ratio of Bax/Bcl-2 was higher in the Fe3O4-MNP-DNR-5-BrTet and Fe3O4-MNP groups than other groups, and there was a significant difference between the Fe3O4-MNP-DNR-5-BrTet group and the other groups (P < 0.05). Furthermore, P-glycoprotein expression was significantly lower in the Fe3O4-MNP-DNR-5-BrTet group than in the other groups (P < 0.05). Interestingly, Fe3O4-MNP-DNR-5-BrTet was more effective than Fe3O4-MNP (P < 0.05).

Discussion

Chemotherapy is still the main method for the majority of tumor therapeutics. However, 90% of tumor chemotherapy failure due to multidrug resistance,18 the mechanism of which is complex. P-glycoprotein-mediated multidrug resistance is the major cause of failure of chemotherapy. P-glycoprotein overexpressed in multidrug-resistant cancer
cells could induce the chemotherapy drugs to pump from the cells. Unfortunately, no P-glycoprotein inhibitors have been approved for clinical use after the failure of valspodar (PSC-833). On the other hand, apoptosis is an important metabolic step in regulating cell numbers and their growth, and multiple antiapoptotic signals have been shown to enable cancer cells to evade destruction by chemotherapeutic drugs. Proteins of the Bcl-2 family have either proapoptotic or antiapoptotic activity and regulate the mitochondrial pathway in apoptosis. However, Bax and Bcl-2 expression is abnormal in hematologic malignances, increasing by up to 21%. Caspase-3 is the most characterized effector caspase, and its activation leads to the final stages of cell death. If Bcl-2 is highly expressed, the caspase-3 precursor cannot be activated and the apoptosis pathway is blocked, leading to disordered metabolism and tumor development. Therefore, there is an urgent global need to develop more effective strategies to overcome multidrug resistance.

In recent years, intensive research activity has been focused on certain Chinese herbal agents, which are safe and partly able to reverse multidrug resistance in cancer cells, and it has been found that 5-BrTet may be one such agent. 5-BrTet combined with chemotherapy would not increase the toxic effects or pharmacokinetic activity of a chemotherapeutic agent. It is worth noting that considerable attention has been paid to nanoparticles and hyperthermia in developing rational and multifunctional compound therapeutics for cancer multidrug-resistant reversal.
Many researchers have shown that chemotherapeutic agents loaded into nanoparticles have increased efficacy, solubility, and low toxicity, and that the drug is protected against chemical and biological degradation. Because of these advantages, nanoparticles can be considered to be potential chemotherapeutic drug carriers for treating multidrug-resistant cancers. Interestingly, one study of nanoparticles loaded with a chemotherapeutic agent has shown reversal of multidrug resistance. At present, Fe₃O₄ is one of the most commonly used nanoparticle materials, with low toxicity, magnetic properties, and minimal impact on body metabolism. In order to make the magnetic nanoparticles accumulate locally at the tumor site, an external alternating magnetic field is usually required, as well as magnetic nanoparticles with additional hyperthermia.

Hyperthermia is an old but nowadays rapidly developing method of treating cancer, whereby a temperature of 40°C–45°C is considered optimal for hyperthermia. However, magnetic nanoparticles interact with each other in the magnetic field and this interaction inevitably influences the efficiency of hyperthermia. Milleron and Bratton demonstrated that hyperthermia could increase local drug concentration and cause apoptosis of cancer cells via the mitochondrial pathway. Another study reported that heat generated in this way was more homogeneous than heat generated using a macroscopic implant, so it is rational to target tumor tissue using locally concentrated magnetic nanoparticles. There is evidence in the literature that hyperthermia can cause local drug accumulation in tumor tissue, leading to apoptosis of cancer cells and a change in the microenvironment of the cancer cell, which in turn affects anticancer immunity in the body. Sonvico et al treated tumor-bearing mice with a magnetic nanomedicine mediated hyperthermia, and 12 days after treatment, the nanomedicine in local tumor decreased to 50% of the dose of the drug at the beginning of the treatment. In our study, with the addition of hyperthermia, tumor temperature was higher in mice treated with Fe₃O₄-MNP or Fe₃O₄-MNP-DNR-5-BrTet than in the other groups, and was maintained at a stable level, with no change in temperature at other body sites in the mice. These results are in agreement with the histopathologic observation of an obvious apoptosis phenomenon in cancer cells in the mice treated with Fe₃O₄-MNP or Fe₃O₄-MNP-DNR-5-BrTet; the inhibition rate in the Fe₃O₄-MNP-DNR-5-BrTet group was much higher than in the other groups after 4 days of treatment. Furthermore, P-glycoprotein and Bcl-2 expression in the Fe₃O₄-MNP-DNR-5-BrTet group was markedly decreased, that of caspase-3 was

---

**Figure 6** Expression of P-glycoprotein and apoptosis-related protein after treatment. Notes: (1) Control, (2) DNR, (3) DNR and 5-BrTet, (4) Fe₃O₄-MNP, and (5) Fe₃O₄-MNP-DNR-5-BrTet. Abbreviations: P-gp, P-glycoprotein; DNR, daunorubicin; 5-BrTet, 5-bromotetrandrine; MNP-Fe₃O₄, magnetic nanoparticles of Fe₃O₄.
Remarkably increased, and the proportion of Bax and Bcl-2 was significantly increased. According to our previous research, $\text{Fe}_3\text{O}_4-\text{MNP-DNR-5-BrTet}$ can release a drug in a sustained manner for longer than 12 days, so $\text{Fe}_3\text{O}_4-\text{MNP-DNR-5-BrTet}$ with hyperthermia in vivo could efficiently overcome tumor multidrug resistance for 12 days by releasing DNR and 5-Br-Tet from $\text{Fe}_3\text{O}_4-\text{MNP}$. In the present study, tumor volume continued to decrease over 12 days, and nanoparticles were observed in the tumor tissue on histopathologic examination after a single treatment with $\text{Fe}_3\text{O}_4-\text{MNP-DNR-5-BrTet}$. Meanwhile, we found that the same dose of DNR with 5-BrTet only decreased the speed of tumor growth and had much less effect on overcoming multidrug resistance than did $\text{Fe}_3\text{O}_4-\text{MNP-DNR-5-BrTet}$. Furthermore, compared with previous research, the addition of hyperthermia not only caused $\text{Fe}_3\text{O}_4-\text{MNP}$ to be a more effective treatment, but also improved the efficiency of $\text{Fe}_3\text{O}_4-\text{MNP-DNR-5-BrTet}$ to a greater extent than did daily administration without hyperthermia. Notably, all the nude mice remained alive, and no adverse reactions were observed in the tumor tissue on histopathologic examination after administration of $\text{Fe}_3\text{O}_4-\text{MNP-DNR-5-BrTet}$. Thus, $\text{Fe}_3\text{O}_4-\text{MNP-DNR-5-BrTet}$ with hyperthermia has decisive advantages in the treatment of local malignant tumor tissue.

**Conclusion**

In conclusion, $\text{Fe}_3\text{O}_4-\text{MNP-DNR-5-BrTet}$ with addition of hyperthermia as a multifunctional strategy could efficiently overcome multidrug-resistant leukemia by downregulating P-glycoprotein expression and upregulating the ratio of Bax/Bcl-2. These findings demonstrate that $\text{Fe}_3\text{O}_4-\text{MNP-DNR-5-BrTet}$ with hyperthermia may be a potential approach to reverse multidrug-resistant leukemia.

**Acknowledgment**

This work was supported by the 973 National Nature Science Foundation of People’s Republic of China (2010CB732404), the National Nature Science Project of the People’s Republic of China (81170492), and the Key Subject Foundation of Jiangsu Province.

**Disclosure**

The authors report no conflicts of interests in this work.

**References**


